# A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer

> **NCT01461057** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 30 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Pertuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01461057
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-06
- **Primary completion:** 2015-03-01
- **Final completion:** 2017-10-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01461057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01461057, "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01461057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*